This article was originally posted on Pharma Boardroom May 31, 2023 | Justin Wu, 2023 Spring Intern, Bridge Consulting Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic […]
The global convergence on Africa’s vaccine manufacturing agenda
mRNA prototype from CNBG at a Scientific and Technological Innovation Exhibition in China | Source: New York Times September 14, 2022 | Nandika Nair, 2022 Summer Intern, Bridge Consulting In this article, we touch upon: The advancement in China’s vaccine R&D over time and after the COVID-19 outbreak The development of Chinese vaccines based on more […]
A staff member of Sinopharm is handling the test vaccine samples | Source: China Daily September 6, 2022 | By Zoe Leung, Associate; Stefania Jiang, Junior Associate, Bridge Consulting What Happened? On 23 August 2022, the World Health Organization (WHO) announced that China’s National Regulatory Authority (NRA) for vaccines had reached a functional maturity level […]
Families lining up to receive the “sugar pill” | Source: CGTN